This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.

BOSTON -- Patients with severe, uncontrolled asthma had significantly higher odds of improvement in asthma-related sleep ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber’s rating ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...